Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Mansoor Raza Mirza sold 2,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $12.00, for a total transaction of $24,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mansoor Raza Mirza also recently made the following trade(s):

  • On Friday, September 15th, Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00.
  • On Monday, September 11th, Mansoor Raza Mirza sold 118 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $11.00, for a total transaction of $1,298.00.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded down 0.61% during trading on Friday, reaching $11.41. 20,933 shares of the company’s stock traded hands. The stock’s market cap is $537.84 million. Karyopharm Therapeutics Inc. has a 52-week low of $6.27 and a 52-week high of $14.63. The company’s 50 day moving average is $10.30 and its 200-day moving average is $9.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The business’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.84) EPS. On average, analysts anticipate that Karyopharm Therapeutics Inc. will post ($2.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Mansoor Raza Mirza Sells 2,000 Shares of Karyopharm Therapeutics Inc. (KPTI) Stock” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/06/mansoor-raza-mirza-sells-2000-shares-of-karyopharm-therapeutics-inc-kpti-stock.html.

KPTI has been the topic of a number of recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $19.00 price target (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.67.

Several hedge funds have recently bought and sold shares of KPTI. Voya Investment Management LLC increased its position in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Karyopharm Therapeutics in the second quarter worth approximately $136,000. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics in the second quarter worth approximately $202,000. American International Group Inc. increased its position in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new position in shares of Karyopharm Therapeutics in the second quarter worth approximately $235,000. Institutional investors own 58.97% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.